Podcast

Diabetes Dialogue: Optimizing CGM Uptake in Primary Care

In the first of 4 special edition ADA 2022 episodes, hosts Drs. Diana Isaacs and Natalie Bellini take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics's Insulin-Only Bionic Pancreas.

Nowhere is there a grander showcase of the latest updates in diabetes management than the American Diabetes Association Scientific Sessions. This year, at ADA 82nd Scientific Sessions, one of the prevailing themes was the advancement of continuous glucose monitoring (CGM) technology and strategies for optimizing uptake of these devices.

In this special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, co-hosts Diana Isaacs, PharmD, a clinical pharmacy specialist and diabetes care and education specialist at Cleveland Clinic, and Natalie Bellini, DNP, an endocrine nurse practitioner at R&B Medical Group, take on the role of interviewers and discuss optimizing CGM uptake in primary care settings with Tamara Oser, MD, and Sean Oser, MD.

Husband and wife, Tamara Oser, MD, serves as the director of the Primary Care Diabetes Lab and Sean Oser, MD, serves as the medical director of UC Health - Lone Tree. Together, the Osers are leading an initiative to implement CGM programs in 60 primary care practices across the state of Colorado. In the episode, the Osers discuss their experience, optimizing CGM uptake, and provide insight on their experience with Beta Bionics’ Insulin-Only Bionic Pancreas.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives is available in an audio-only format on Spotify and Apple Podcasts.

Related Videos
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
4 experts are featured in this series.
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.